Pituitary tumor prognostication: WHO is really the best?

Eur J Endocrinol. 2023 Jul 20;189(1):R1-R3. doi: 10.1093/ejendo/lvad080.

Authors

Nicolas Sahakian¹, Henry Dufour², Thierry Brue¹, Thomas Cuny¹

Affiliations

¹ Department of Endocrinology, Aix Marseille University, MMG, INSERM U1251, MARMARA Institute, APHM, Hôpital de la Conception, CRMR HYPO, Marseille 13005, France.
² Department of Neurosurgery, Aix Marseille University, MMG, INSERM U1251, MARMARA Institute, APHM, Hôpital de la Timone, CRMR HYPO, Marseille 13005, France.

PMID: 37440700
DOI: 10.1093/ejendo/lvad080

No abstract available

Keywords: Ki67; P53; WHO; classification; pituitary tumor.

Publication types

Comment

MeSH terms

Biomarkers, Tumor
Humans
Ki-67 Antigen / metabolism
Pituitary Neoplasms* / diagnosis
Pituitary Neoplasms* / pathology
Prognosis
Tumor Suppressor Protein p53
World Health Organization

Substances

Biomarkers, Tumor
Ki-67 Antigen
Tumor Suppressor Protein p53